Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

LifeTein's Synthetic Scorpion Toxin Peptides Helped Scientists Unravel Chronic Pain Mechanisms | LifeTein Peptide Blog

Researchers at the University of California, San Francisco (UCSF), in collaboration with LifeTein, have made a groundbreaking discovery in the field of pain management. LifeTein’s expertise in peptide synthesis was crucial in developing synthetic scorpion toxi

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Researchers at the University of California, San Francisco (UCSF), in collaboration with LifeTein, have made a groundbreaking discovery in the field of pain management. LifeTein’s expertise in peptide synthesis was crucial in developing synthetic scorpion toxin peptides that specifically target the “wasabi receptor,” a key player in the body’s response to certain types of pain.

The wasabi receptor, scientifically known as TRPA1, is an ion channel protein that triggers the familiar sinus-clearing or eye-watering sensation experienced when consuming wasabi or cutting onions. This receptor is also implicated in the perception of chronic pain.

The focus of this research is a peptide derived from scorpion toxin, referred to as WaTx. Remarkably, WaTx, synthesized by LifeTein, can activate the TRPA1 receptor, mimicking the pain response to irritants. Unlike other molecules, WaTx has the unique ability to penetrate cell membranes directly, bypassing the need for channel proteins. This property makes it an invaluable tool for studying chronic pain and inflammation.

In addition to its research applications, WaTx holds promise for the development of new, non-opioid pain therapies. It has been observed to induce pain and pain hypersensitivity without causing neurogenic inflammation, a common side effect of many pain treatments.

Expanding the Horizon: Spider Venom and Chronic Pain

Further expanding on this concept, a study titled “Identification and Characterization of ProTx-III [μ-TRTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula Thrixopelma pruriens” delves into the potential of spider venoms in pain management. This study, conducted by F. C. Cardoso and colleagues, discovered a novel inhibitor, μ-TRTX-Tp1a (Tp1a), from the venom of the Peruvian green-velvet tarantula. Tp1a selectively inhibits human NaV1.

7 channels, which are key contributors to pain perception.

The study found that Tp1a, both in its recombinant and synthetic forms, preferentially targets NaV1.7 channels, offering a new avenue for analgesic drug development. Unlike many other spider toxins affecting NaV channels, Tp1a does not significantly alter the voltage dependence of activation or inactivation of these channels. This unique feature of Tp1a was demonstrated to be effective in reversing spontaneous pain in animal models.

The structural analysis of Tp1a revealed an inhibitor cystine knot motif, common in spider toxins but with distinct pharmacological properties that could be crucial in developing more selective and potent treatments for chronic pain.

Conclusion

The research at UCSF, along with the findings on spider venom peptides and the significant contributions of LifeTein in peptide synthesis, represents a significant step forward in understanding and potentially treating chronic pain. These discoveries highlight the vast potential of natural toxins in medical research, offering hope for more effective and safer pain management strategies in the future.

Reference:

Lin King, J. V., Emrick, J. J., Kelly, M. J. S., Herzig, V., King, G. F., Medzihradszky, K. F., & Julius, D. (2019). A Cell-Penetrating Scorpion Toxin Enables Mode-Specific Modulation of TRPA1 and Pain. Cell. doi:10.1016/j.cell.2019.07.014

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Structural Studies

Rigid spacers help stabilize peptide conformations in NMR or crystallography studies, providing more precise structural data.Find out more about peptide synthesis here.

Source: lifetein.com ↗

Clinical Trials and Research

Several clinical trials have explored the use of PADRE in cancer vaccines. For instance, vaccines targeting Mucin 1 (MUC1), a glycoprotein overexpressed in many cancers, have shown promising results when combined with PADRE. These vaccines have demonstrated the ability to elicit strong immune responses, including the production of antibodies against cancer-specific antigens.

Source: lifetein.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to solubilize my synthetic peptides? #

Please refer to this FAQ for details: Handling and Storage of Synthetic Peptides. If the peptides are still cloudy, or turbid, you may have reached the limit of solubility. When the peptides are insoluble in the buffer, please try to sonicate, centrifuge, and lyophilize the peptide. Make sure to break the lyophilized lumps into a fine powder. Then try a small volume of a good agent 8M Urea, NMP, DMF, or DMSO to dissolve the peptide. Then dilute with water or your desired buffer. For peptides with Arg or LYs, you should try to lower the pH to 6 because the protonated amino acids will help solubility. Sonication and the following solvents may help with difficult peptides: 1) Begin with 100 % acetonitrile then dilute with water until 50% 2) Begin with 100% DMSO then dilute with water until 30 % 3) Dissolve it with 8M Urea 4) Dissolve it with 6 or 8 M Guanidine hydrochloride 5) 6M GuHCL, 0.05% TFA, pH2, 6) 100% TFA 7) 40% AcOH, 30%ACN, 30% water

Source: lifetein.com ↗
Storage reference

Storage temperatures and conditions #

For many of our antibodies, freezing at -20 C or -80 C in small aliquots is the optimal storage condition. Aliquotting minimizes damage due to freezing and thawing, as well as contamination introduced by pipetting from a single vial multiple times. Aliquots should be no smaller than 10 µl. Upon receiving the antibody, centrifuge at 5,000 x g for 30 seconds to pull down the solution, and transfer aliquots into low-protein-binding microcentrifuge tubes. Antibodies should be frozen as soon as possible, storage at 4 C upon receipt of the antibody is acceptable for one to two weeks, followed by freezing for long-term storage. To prevent microbial contamination, sodium azide can be added to an antibody preparation to a final concentration of 0.02% (w/v). If using antibodies for in vivo studies, please be sure to use preparations that do not contain sodium azide. This antimicrobial agent blocks the cytochrome electron transport system. Sodium azide will interfere with any conjugation that involves an amine group and should be removed before proceeding with the conjugation. After conjugation, antibodies can be stored in sodium azide but 0.01% thimerosal (Merthiolate), which does not have a primary amine, is an acceptable alternative. Sodium azide can be removed from antibody solutions by dialysis or gel filtration. The molecular weight of IgG is 150,000 daltons (IgM is ~ 600,000); the molecular weight of sodium azide is 65 daltons. A micro-dialysis unit with a cut off at 14,000 dalt…

Source: lifetein.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides